


ONC 201 Studie

Assoc. Prof. Priv.-Doz. Dr. Anna Sophie Berghoff
Klinische Abteilung für Onkologie

Study design

Study design



Study Inclusion Criteria

Patients have to meet all of the following criteria to be included into the study.

Inclusion criteria

- Body weight ≥ 10 kg at time of randomization.
- Histologically diagnosed H3 K27M-mutant diffuse glioma
- At least one, high-quality, contrast-enhanced MRI of the brain
 - obtained before radiotherapy and post resection (if applicable)
- At least one, high-quality, contrast-enhanced MRI of the brain obtained 2 to 6 weeks after completion of frontline radiotherapy.
- Completed standard frontline radiotherapy within 2 to 6 weeks prior to randomization.
- KPS ≥ 70
- Stable or decreasing dose of corticosteroids and anti-seizure medications for 7 days prior to randomization

Exclusion Criteria

Patients meeting any of the following criteria will be excluded from the study.

Exclusion Criteria

- Primary spinal tumor
- Diffuse intrinsic pontine glioma
- Evidence of leptomeningeal spread of disease or cerebrospinal fluid dissemination
- New lesion(s) outside of the radiation field
- Received whole-brain radiotherapy
- Received proton therapy for glioma
- See Protocol for a more detailed list of exclusion criteria.

Contact Information

Medical University Vienna

- PI: Anna Berghoff
 - Email: anna.berghoff@meduniwien.ac.at
 - Telefon: +43 (0)1 40400 – 44470
- Study coordinator: Calvin Abdel Malak
 - Email: calvin.abdelmalak@meduniwien.ac.at
 - Telefon: +43 (0)1 40400 – 44210